• Sunitinib: Multi-Targeted RTK Inhibitor for RCC Research Wor

  2026-05-09

  Sunitinib empowers cancer researchers with precision RTK pathway inhibition and apoptosis induction, especially in renal cell carcinoma (RCC) and nasopharyngeal carcinoma models. This article decodes recent advances—including combination strategies to overcome resistance—and delivers actionable, stepwise protocols with troubleshooting tips for robust experimental outcomes.

• HO-1-Mediated ROS Modulation Disrupts HBV Replication Pathwa

  2026-05-08

  This study reveals that isochlorogenic acid A impairs hepatitis B virus (HBV) replication by upregulating heme oxygenase-1 (HO-1) and altering intracellular reactive oxygen species (ROS) levels. The findings underscore HO-1 as a multifaceted regulator of HBV morphogenesis and suggest new experimental routes for targeting viral persistence.

• Dual “Engage & Evasion” Strategy Boosts EV Therapy Efficacy

  2026-05-08

  Liu et al. introduce a two-step 'Engage & Evasion' approach to overcome rapid mononuclear phagocyte system (MPS) clearance of extracellular vesicles (EVs), enhancing their systemic retention and therapeutic impact in ischemic disease models. This strategy leverages sequential MPS saturation and CD47-enriched EV delivery, offering a promising advance for targeted regenerative therapies.

• ONX-0914 (PR-957): Redefining Immunoproteasome Inhibition

  2026-05-07

  This thought-leadership article explores how ONX-0914 (PR-957) advances selective immunoproteasome inhibition, offering mechanistic insight, protocol guidance, and strategic recommendations for translational researchers. Drawing from recent breast cancer proteasome heterogeneity findings and APExBIO’s robust product data, it connects molecular rationale with practical workflow and clinical impact.

• Cyclopamine (SKU A8340): Reliable Hedgehog Inhibition in Can

  2026-05-07

  This article provides a scenario-driven, evidence-based exploration of Cyclopamine (SKU A8340) as a Hedgehog signaling inhibitor for cancer and developmental biology research. Real-world lab challenges are addressed with practical solutions, protocol optimization, and vendor selection insights, all grounded in peer-reviewed data and APExBIO’s product reliability.

• Z-YVAD-FMK: Precision Caspase-1 Inhibitor for Pyroptosis Ass

  2026-05-06

  Z-YVAD-FMK empowers researchers to dissect caspase-1–mediated cell death with exceptional selectivity and workflow flexibility. Its irreversible inhibition profile, high cell permeability, and robust performance in apoptosis and inflammasome studies set the stage for advanced experimental design and troubleshooting.

• Angiotensin III: Advanced Applications in RAAS Research

  2026-05-06

  Angiotensin III (human, mouse) empowers high-fidelity modeling of RAAS-mediated cardiovascular and neuroendocrine pathways, with peer-reviewed evidence linking its activity to both classical and emerging disease contexts. This guide translates recent mechanistic insights and workflow best practices into actionable protocols—optimizing the impact of APExBIO’s validated peptide in complex experimental systems.

• Pharmacokinetic Variability of CSBTA Alkaloids in MASH: Insi

  2026-05-05

  This study systematically characterizes the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mouse models of metabolic dysfunction-associated steatohepatitis (MASH) induced by a high-fat, high-cholesterol diet. The research highlights how pathological changes alter drug metabolizing enzymes and transporters, informing dosing strategies for MASLD/MASH therapies.

• Genistein in Mechanotransduction: Bridging Tyrosine Kinase I

  2026-05-05

  Explore how Genistein, a selective tyrosine kinase inhibitor, advances cancer chemoprevention by modulating cytoskeleton-dependent autophagy. This in-depth analysis reveals unique mechanistic insights and protocol guidance not found in standard workflows.

• Risedronate Sodium: FPP Synthase Inhibitor in Translational

  2026-05-04

  Risedronate Sodium, a potent FPP synthase inhibitor, is transforming bone metabolism and cancer research through advanced delivery methods and robust in vitro and in vivo models. This article details experimental workflows, troubleshooting, and innovative protocol enhancements enabled by APExBIO's Risedronate Sodium, with actionable insights from recent microneedle patch research.

• Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mic

  2026-05-04

  This study systematically analyzes the pharmacokinetic variability of Corydalis saxicola Bunting total alkaloids (CSBTA) in a high-fat, high-cholesterol diet (HFHCD)-induced mouse model of metabolic dysfunction-associated steatohepatitis (MASH). By integrating tissue distribution, transporter activity, and metabolic enzyme expression, the research reveals disease-state-dependent changes in drug exposure, with implications for rationalizing clinical dosing in MASLD/MASH.

• Basic Protein Native PAGE Gel Kit: Native-State Protein Elec

  2026-05-03

  The Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit (PI ≤ 7.0) enables native protein gel electrophoresis for acidic proteins, preserving biological activity and providing high-resolution separation. The kit, manufactured by APExBIO, delivers reliable results for protein purification and identification without the use of denaturants. Performance benchmarks and workflow parameters are supported by both product specifications and peer-reviewed literature.

• Indometacin Sodium: Optimizing Inflammation and Differentiat

  2026-05-02

  Indometacin Sodium Trihydrate (APExBIO) goes beyond conventional COX inhibition, empowering advanced inflammation and neuroregeneration workflows through robust, reproducible assay performance. This guide translates clinical and preclinical evidence into actionable laboratory protocols, troubleshooting strategies, and comparative insights for translational research.

• Advancing In Vitro Evaluation of Cancer Drug Responses

  2026-05-01

  Schwartz's dissertation introduces a nuanced in vitro framework for distinguishing between proliferative arrest and cell death in anti-cancer drug evaluation. This approach sharpens the interpretation of drug response assays, offering deeper insights for translational cancer biology.

• PERK-JAK1–STAT3 Axis Drives Pyroptosis in Disc Degeneration

  2026-05-01

  This study elucidates how sustained endoplasmic reticulum stress (ERS) accelerates pyroptosis in nucleus pulposus cells via PERK-dependent JAK1–STAT3 signaling, establishing a mechanistic link to intervertebral disc degeneration. The findings highlight therapeutic potential in targeting the PERK/eIF2α/ATF4-JAK1–STAT3 axis to mitigate inflammation-driven disc pathology.

15835 records 1/1056 page Next 12345 下5页 Last page